Aging and reprogramming: A two-way street

Department of Genetics, Stanford University, Stanford, CA 94305, USA.
Current opinion in cell biology (Impact Factor: 8.47). 11/2012; 24(6). DOI: 10.1016/
Source: PubMed


Aging is accompanied by the functional decline of cells, tissues, and organs, as well as a striking increase in a wide range of diseases. The reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) opens new avenues for the aging field and has important applications for therapeutic treatments of age-related diseases. Here we review emerging studies on how aging and age-related pathways influence iPSC generation and property. We discuss the exciting possibility that reverting to a pluripotent stem cell stage erases several deficits associated with aging and offers new strategies for rejuvenation. Finally, we argue that reprogramming provides a unique opportunity to model aging and perhaps exceptional longevity.

Download full-text


Available from: Anne Brunet,
  • Source
    • "By contrast, the modeling of late-onset disorders has often failed to faithfully recapitulate the late-stage features of the disease phenotypes, such as macromolecular protein aggregates ( plaques) or the progressive deterioration of neuronal structures resulting in cell death (Srikanth and Young-Pearse, 2014). The difficulties in modeling late-onset disease phenotypes may be related to the reset of donor age in human pluripotent stem cells (hPSCs) following reprogramming (Suhr et al., 2010; Lapasset et al., 2011; Mahmoudi and Brunet, 2012; Frobel et al., 2014). The resulting hPSCs give rise to cells that typically show the behavior of fetal stage cells following in vitro differentiation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In contrast to the successful modeling of early-onset disorders using patient-specific cells, modeling of late-onset neurodegenerative diseases such as Parkinson's disease remains a challenge. This might be related to the often ignored fact that current induced pluripotent stem cell (iPSC) differentiation protocols yield cells that typically show the behavior of fetal stage cells. Acknowledging aging as a contributing factor in late-onset neurodegenerative disorders represents an important step on the road towards faithfully recreating these diseases in vitro. Here, we summarize progress in the field and review the strategies and challenges for triggering late-onset disease phenotypes.
    Development 09/2015; 142(18):3085-3089. DOI:10.1242/dev.120667 · 6.46 Impact Factor
  • Source
    • "Research article variety of different reprogramming factors, reprogramming enhancers, and cell types have been evaluated (Liao et al., 2008; Judson et al., 2009; Mali et al., 2010; Cheng et al., 2011; Niibe et al., 2011; Szablowska-Gadomska et al., 2011; Zhang et al., 2011; Li and Rana, 2012; Lin et al., 2012; Liu et al., 2012; Mahmoudi and Brunet, 2012; Okita et al., 2013; Zhang and Wu, 2013). Of the accessible cell types used for iPSC generation, the reprogramming of keratinocytes has been shown to be as much as 100-fold more efficient and at least twofold faster than the reprogramming of dermal fibroblasts (Aasen et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Next-generation and Sanger sequencing were combined to identify disease-causing USH2A mutations in an adult patient with autosomal recessive RP. Induced pluripotent stem cells (iPSCs), generated from the patient’s keratinocytes, were differentiated into multi-layer eyecup-like structures with features of human retinal precursor cells. The inner layer of the eyecups contained photoreceptor precursor cells that expressed photoreceptor markers and exhibited axonemes and basal bodies characteristic of outer segments. Analysis of the USH2A transcripts of these cells revealed that one of the patient’s mutations causes exonification of intron 40, a translation frameshift and a premature stop codon. Western blotting revealed upregulation of GRP78 and GRP94, suggesting that the patient’s other USH2A variant (Arg4192His) causes disease through protein misfolding and ER stress. Transplantation into 4-day-old immunodeficient Crb1−/− mice resulted in the formation of morphologically and immunohistochemically recognizable photoreceptor cells, suggesting that the mutations in this patient act via post-developmental photoreceptor degeneration. DOI:
    eLife Sciences 08/2013; 2(2):e00824. DOI:10.7554/eLife.00824 · 9.32 Impact Factor
  • Source
    • "It is now clear that reprogramming efficiency is sensitive to various factors, among them the genetic background of the source of cells, the tissue source, the reprogramming method, and the combination of the reprogramming factors. In addition, recent high impact studies suggested that aging is a direct barrier to the generation of iPSCs (Banito et al. 2009; Mahmoudi and Brunet 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of induced pluripotent stem cells (iPSCs) has the potential to revolutionize the field of regenerative medicine. In the past few years, iPSCs have been the subject of intensive research towards their application in disease modeling and drug screening. In the future, these cells may be applied in cell therapy to replace or regenerate tissues by autologous transplantation. However, two major hurdles need to be resolved in order to reach the later goal: the low reprogramming efficiency and the safety risks, such as the integration of foreign DNA into the genome of the cells and the tumor formation potential arising from transplantation of residual undifferentiated cells. Recently, aging emerged as one of the barriers that accounts, at least in part, for the low reprogramming efficiency of bona fide iPSCs. Here, we review the molecular pathways linking aging and reprogramming along with the unanswered questions in the field. We discuss whether reprogramming rejuvenates the molecular and cellular features associated with age, and present the recent advances with iPSC-based models, contributing to our understanding of physiological and premature aging.
    Biogerontology 08/2013; 14(6). DOI:10.1007/s10522-013-9455-2 · 3.29 Impact Factor
Show more